Alteplase for the Treatment of Acute Ischemic Stroke in Patients with Low NIHSS and Not Clearly-Disabling Deficits: Primary Results of the PRISMS Trial

Purpose: To evaluate the treatment outcomes with IV alteplase for non-disabling minor deficit strokes (NIHSS score 0-5)

Trial Design: N=313. Randomized, active-controlled, double-blinded, phase 3b trial. mRS @ 90 days comparing IV alteplase (0.9 mg/kg, max 90 mg) + placebo aspirin vs. placebo alteplase + aspirin (325 mg) at ≤3 hours of last known well.

Primary Endpoints: 90-day functional outcome (mRS 0-1)

90-day outcomes	alteplase	control	Adjusted risk difference
mRS 0-1	78.2%	81.5%	-1.10%

This trial was stopped early because of delayed enrollment targets. Incomplete, non-conclusive findings suggest that AIS benefits with alteplase may not apply to patients with *non-disabling* strokes of minor severity. (Low NIHSS and Not Clearly-Disabling Deficits)

Presented by: Pooja Khatri, 2018 International Stroke Conference, Los Angeles, CA

American Heart Association | American Stroke Association
life is why™